Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
暂无分享,去创建一个
B. Pégourié | S. Chevret | M. Macro | C. Vigneau | F. Suarez | B. Arnulf | A. Karras | B. Royer | A. Jaccard | J. Fermand | F. Bridoux | P. Gobert | L. Karlin | M. Tiab | K. Belhadj | D. Caillot | V. Audard | S. Manier | K. Augeul-Meunier | B. Joly | D. Roos‐Weil | S. Caillard | Sébastien Delbès | N. Blin | N. Rabot | Emilie Cornec Le Gall | Nina Arakelyan-Laboure | D. Roos-Weil
[1] A. Pani,et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: A multicenter retrospective study. , 2020, Blood.
[2] H. Goldschmidt,et al. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. , 2019, Clinical lymphoma, myeloma & leukemia.
[3] M. Dimopoulos,et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. , 2019, Blood.
[4] B. Pégourié,et al. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial , 2017, JAMA.
[5] M. Dimopoulos,et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. , 2017, Blood advances.
[6] M. Dimopoulos,et al. Proteasome inhibitor associated thrombotic microangiopathy , 2016, American journal of hematology.
[7] B. Pégourié,et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. , 2016, Blood.
[8] M. Dimopoulos,et al. Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis , 2016, American journal of hematology.
[9] M. Suneja,et al. Thrombotic microangiopathy associated with proteasome inhibitors , 2015, Clinical kidney journal.
[10] D. Dingli,et al. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both , 2015, Leukemia & lymphoma.
[11] A. Dispenzieri,et al. Diagnosis of monoclonal gammopathy of renal significance. , 2015, Kidney international.
[12] D. Hose,et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma , 2015, Leukemia.
[13] N. Heyne,et al. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] M. Boccadoro,et al. Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA , 2010, European journal of haematology.
[15] A. Dispenzieri,et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. , 2008, Kidney international.
[16] Joseph D Tariman,et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. , 2007, Blood.
[17] John A Kellum,et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.
[18] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[19] Amit X Garg,et al. Plasma Exchange When Myeloma Presents as Acute Renal Failure , 2005, Annals of Internal Medicine.
[20] Kenneth C. Anderson,et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.
[21] Nathan Mantel,et al. Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data , 1974 .
[22] A. Dispenzieri,et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma , 2012, Nature Reviews Nephrology.
[23] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.